Full Answer
Is Chemours (cc) outperforming other chemical-diversified stocks this year?
Looking more specifically, Chemours belongs to the Chemical-Diversified industry, which includes 38 individual stocks and currently sits at #57 in the Zacks Industry Rank. On average, stocks in this group have lost 6.6% this year, meaning that CC is performing better in terms of year-to-date returns. Cabot is also part of the same industry.
Why did Chemours'sales slow in Q4?
To be fair, however, there are other moving parts in the picture. For example, sales in Chemours' titanium division (accounting for 55% of fourth-quarter sales) slowed down in the quarter because of issues in the auto sector.
How did Chemours Corporation’s sales recover during the pandemic?
Over both periods, Chemours said the recovery in global demand from the effects of the pandemic supported its sales increases. So far, the story seems pretty good, noting the top-line estimate beat.
Should you buy Chemours and Cabot in the basic materials sector?
Investors interested in the Basic Materials sector may want to keep a close eye on Chemours and Cabot as they attempt to continue their solid performance.
See more
Is Chemours a good stock to buy?
Chemours currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
What happened Chemours?
What happened. Shares of Chemours (CC 1.90%), a specialty chemical company, fell sharply at the open of trading on Friday, losing as much as 14.5% of their value in the first few minutes of trading. The big story was the company's earnings release, which hit the market after the close on Thursday.
Are DuPont and Chemours the same company?
DuPont filed its initial Form 10 with the SEC in December 2014 and announced that the new company would be called "The Chemours Company". The spin-off to DuPont shareholders was completed on July 1, 2015, and Chemours' stock began trading on the New York Stock Exchange on the same date.
Who bought Chemours?
DraslovkaDraslovka, a multi-family-owned Czech speciality chemicals firm, has agreed to acquire the Mining Solutions business of Chemours for $520 million, or 10 x EBITDA in 2020. This came shortly after its agreement to buy Sasol's sodium cyanide business $101.7 million.
What happened
Shares of The Chemours Company (NYSE: CC) dropped over 20% in July, according to data provided by S&P Global Market Intelligence. There wasn't any major news, but investors were certainly not looking forward to second-quarter 2019 results, due to be released on the first day of August.
So what
CEO Mark Vergnano summed up the Q2 performance by stating, "we are clearly not satisfied with these results." In that time span, Chemours reported an 11% year-over-year decline in revenue for its fluoroproducts division, which includes its Opteon refrigerants, and a 34% decline in revenue for its TiO2 segment.
Now what
Chemours finds itself in a tough position. Its core TiO2 segment is facing commodity and cyclical pressures, while its fluoroproducts division faces competitive pressures and questions over the safety of the chemistry involved. Until the business proves it's capable of weathering the storm, investors might want to tread lightly with the stock.
Investors were anticipating weak second-quarter 2019 operating results. They were right
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
What happened
Shares of The Chemours Company ( NYSE:CC) dropped over 20% in July, according to data provided by S&P Global Market Intelligence. There wasn't any major news, but investors were certainly not looking forward to second-quarter 2019 results, due to be released on the first day of August.
So what
CEO Mark Vergnano summed up the Q2 performance by stating, "we are clearly not satisfied with these results." In that time span, Chemours reported an 11% year-over-year decline in revenue for its fluoroproducts division, which includes its Opteon refrigerants, and a 34% decline in revenue for its TiO2 segment.
Now what
Chemours finds itself in a tough position. Its core TiO2 segment is facing commodity and cyclical pressures, while its fluoroproducts division faces competitive pressures and questions over the safety of the chemistry involved. Until the business proves it's capable of weathering the storm, investors might want to tread lightly with the stock.
What happened to Chemours in 2019?
Chemours reported a troubling pattern in the first three months of 2019 in which revenue fell and expenses increased. That sapped operating income from two directions and led to an awful year-over-year comparison for the most important financial metrics.
Where did Maxx graduate from?
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
Is Chemours toxic?
Chemours had a rough start to 2019, and although some of the headwinds could prove temporary, investors cannot overlook the company's toxic legacy stemming from its fluoroproducts division. That legacy could still prove costly, too. The quarterly report filed with the SEC disclosed multiple new lawsuits and complaints brought in the first quarter alone, including towns such as Atlantic City and the Cannon Air Force Base in New Mexico. Therefore, a tumbling share price might not be as tempting as investors initially think.
The company was dealt a blow in a legal battle against its former parent
Lou has followed the markets for more than two decades, developing extensive contacts including industry leaders, consultants, regulators, and labor representatives. He spends a lot of time these days focused on the industrials and financials.
What happened
Shares of Chemours ( NYSE:CC) fell more than 8% on Tuesday, and were down more than 10% earlier in the day, after the chemical company's lawsuit against its former parent was dismissed on technical grounds.
So what
Chemours, a major supplier of titanium dioxide, was spun out of DuPont ( NYSE:DD) in 2015 and held on to a lot of legacy environmental liabilities as part of the separation agreement. Chemours has argued that DuPont's estimates of how much its former subsidiary would be on the hook for were off base and were not prepared in good faith.
Now what
This isn't over, with the appeals process still to play out, but the ruling is a major victory for DuPont and a setback for Chemours.
Latest Stocks Videos
In The Money: Groundhog Day: Mega-Cap Tech Stocks Out From the Shadows? Feb 02, 2022
Zacks
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank.
